Volume 15, Number 10—October 2009
Research
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
Kevin L. Winthrop
, Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue
, Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue
Table 3
Characteristics of 105 pulmonary and nonpulmonary anti–TNF-α therapy–associated cases of NTM disease, US Food and Drug Administration MedWatch database, 1999–2006*
| Characteristic | Pulmonary (n = 59), no. (%) | Extrapulmonary (n = 46), no. (%) |
|---|---|---|
| Mycobacterium avium | 43 (73) | 9 (20)† |
| RGM | 6 (10) | 15 (33)† |
| Age, y | 61 | 63 |
| Female patient | 41 (73) | 25 (54)† |
| Rheumatoid arthritis | 48 (81) | 25 (54)† |
| Infliximab | 40 (68) | 33 (72) |
| Etanercept | 13 (22) | 12 (26) |
*TNF-α, tumor necrosis factor-α; NTM, nontuberculous mycobacteria; RGM, rapidly growing mycobacteria.
†p<0.05 for comparison of pulmonary disease and extrapulmonary disease.
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.